GP531

5-amino-1-[(2R,3R,4S,5R)-5-[(benzylamino)methyl]-3,4-dihydroxyoxolan-2-yl]imidazole-4-carboxamide | 1H-IMIDAZOLE-4-CARBOXAMIDE, 5-AMINO-1-(5-DEOXY-5-((PHENYLMETHYL)AMINO)-.BETA.-D-RIBOFURANOSYL)- | HY-U00116 | 5-Amino-1-[5-(benzylamino)-5-deoxypentofurano

GP531

G647089-5mg

5mg

≥98%

-20°C储存

超低温冰袋运输

GP531 is a potent, second-generation adenosine regulating agent, is pharmacologically silent under basal conditions but increases localized endogenous adenosine during ischemia. In Vivo Low-dose GP531 reduces infarct size by 34% compared with vehicle and reduces the extent of the anatomic no-reflow zone by 31% compared with vehicle. Infarct size and zone of no-reflow in the high dose are reduced by 22% and 16%, respectively. GP531 does not affect hemodynamics or blood flow. GP531 is effective at the lower dose in reducing the severity of ischemic/reperfusion injury, without inducing the adverse hemodynamic effects associated with adenosine administration such as bradycardia and hypotension . GP531 infusion has no effect on heart rate or mean aortic pressure but significantly decreases left ventricular end-diastolic pressure, end-diastolic volume, end-systolic volume and end-diastolic wall stress. GP531 significantly increases left ventricular EF, deceleration time of early mitral inflow velocity and the slope of end-systolic PVR without increasing MVO2. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:Adenosine Receptor

GP531 是一种强效的第二代腺苷调节剂，在基础条件下无药理作用，但在缺血时会增加局部内源性腺苷。

142344-87-4

C16H21N5O4

347.37 g/mol

164444

C1=CC=C(C=C1)CNC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC(=C3N)C(=O)N)O)O

5-amino-1-[(2R,3R,4S,5R)-5-[(benzylamino)methyl]-3,4-dihydroxyoxolan-2-yl]imidazole-4-carboxamide

1S/C16H21N5O4/c17-14-11(15(18)24)20-8-21(14)16-13(23)12(22)10(25-16)7-19-6-9-4-2-1-3-5-9/h1-5,8,10,12-13,16,19,22-23H,6-7,17H2,(H2,18,24)/t10-,12-,13-,16-/m1/s1

LECUGLHMNZTZQB-XNIJJKJLSA-N

C1=CC=C(C=C1)CNCC2C(C(C(O2)N3C=NC(=C3N)C(=O)N)O)O

164444

142344-87-4

5-amino-1-beta-D-(5'-benzylamino-5'-deoxyribofuranosyl)imidazole-4-carboxamide;GP 531;GP-531;GP531

DMSO : 125 mg/mL (359.85 mM; Need ultrasonic)

5

7

6

347.159 Da

347.159 Da

149.000 Ų

25

0

462.000

0

1

-0.400